INSIGHTS ON CELL & GENE COMMERCIALIZATION ISSUES

• Know Your Product, Know Your Path: A Primer On Advanced Therapy Development

  To prevent path-to-market setbacks, it is critical to develop a CMC strategy that proactively identifies scientific and compliance gaps, as well as mitigates risk.

• New Regulatory Survey Findings: Biotech Global Market Access Challenges And Learnings

  To understand biotech companies’ evolving geographic strategies and perceptions, Arriello recently commissioned a transatlantic survey among regulatory, safety, and quality directors at small/medium biotechs, with respondents in Ireland and North America.

• 2025 Forecast For Advanced Therapies

  As we reflect on the lessons from 2024, it’s time to consider what 2025 may hold for the industry. Special attention is given to oligos, mRNA, cell therapies, and AAV.

• What Does InspiroGene Bring To The CGT Space And To The Patients It Serves?

  Joe DePinto, Head of Cell Gene and Advanced Therapies at McKesson, discusses what InspiroGene brings to the cell and gene therapy (CGT) space and the patients it serves.

• Bridging The Gap Between CGT Innovation And Reality

  Learn about the range of services provided by InspiroGene By McKesson and the company’s unique points of difference as a commercial ally to stakeholders in the CGT industry.

• What's Next For Cell And Gene Therapies: Addressing Key Challenges

  Delve into this exploration of the challenges and opportunities facing CGTs, including manufacturing, supply chain logistics, and the need for greater collaboration among stakeholders.

• U.S. Oncologists See Promise In CGTs, But Barriers Loom

  Explore the findings of a survey of 124 U.S. oncologists focused on better understanding the current use of cell and gene therapies (CGTs) and possible barriers to future adoption.

• Optimism For Biopharma In 2025

  In this closing segment from the executive roundtable discussion, our panelists express their confidence in the industry's mission and maintain a positive outlook for the years ahead.

• How Biotechs Can Navigate Market Uncertainty In 2025

  In this segment of the executive roundtable discussion, our panelists weigh in on how to prepare for what may be a challenging financial climate in 2025. 

• Exciting Areas Of Innovation For Cell Therapies

  In this segment of the executive roundtable discussion, our panelists express optimism about the promising future of allogeneic cell therapies and discuss other innovations in the field.